Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.,Oncogene

当前位置： X-MOL 学术 › Oncogene › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
Oncogene ( IF 6.9 ) Pub Date : 2020-02-01 , DOI: 10.1038/s41388-019-1143-5
Ying Jin _{1,

2,

3} , Hua Bao ₄ , Xiuning Le ₅ , Xiaojun Fan ₄ , Ming Tang ₅ , Xun Shi _{1,

2} , Jun Zhao _{1,

2} , Junrong Yan ₆ , Yang Xu ₄ , Kelly Quek ₅ , Yasir Y Elamin ₅ , Jianhua Zhang ₇ , P Andrew Futreal ₇ , Ignacio I Wistuba ₈ , John V Heymach ₅ , Guangyuan Lou _{1,

2} , Lan Shao _{1,

2} , Qiong He _{1,

2} , Chen Lin _{1,

2} , Xue Wu ₄ , Yang W Shao ₆ , Xiaonan Wang ₆ , Jiachen He ₆ , Yamei Chen _{1,

3} , Justin Stebbing ₉ , Ming Chen _{1,

3} , Jianjun Zhang _{5,

7} , Xinmin Yu _{1,

2}

Affiliation

The original version of this Article omitted the following from the Acknowledgements: Professor Stebbing sits on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. This has now been corrected in both the PDF and HTML versions of the Article.

中文翻译：

校正：在有或没有获得性T790M突变的非小细胞肺癌患者中，在TKI治疗期间不同的共同获得性改变和基因组进化。

本文的原始版本在致谢中省略了以下内容：Stebbing教授坐在Celltrion，新加坡生物技术，Vor Biopharma，TLC生物制药和Benevolent AI的SAB上，并已与Lansdowne合作伙伴，Vitruvian和Social Impact Capital以及董事会主席进行了磋商。为BB Biotech Healthcare Trust和Xerion Healthcare提供服务。现在，该文章的PDF和HTML版本均已对此问题进行了更正。

更新日期：2019-12-13

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11